MAD-paclitaxel therapy / Navidea - LARVOL DELTA

Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting (Businesswire) - "The results will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer ('SITC') to be held at the Boston Convention & Exhibition Center in person and virtually November 8-12, 2022....The abstract, 'Synthetic CD206 Targeted Constructs Carrying Paclitaxel or Novel Bisphosphonate Payloads Alter Macrophages Towards Pro-inflammatory Phenotypes; The Paclitaxel Construct Improves the Efficacy of anti-CTLA4 in CT26 Tumors' (Abstract #1161), will be presented as a poster on November 10....In addition to the in vitro work using both the paclitaxel and bisphosphonate carrying constructs, in vivo studies using the MAD-paclitaxel construct in a mouse tumor model demonstrated that this construct increased the efficacy of an approved checkpoint inhibitor therapy, anti-CTLA4, reducing tumor growth by 76% compared to a saline control."

Preclinical • Oncology